Results 101 to 110 of about 231,717 (193)

Multiple Red Flags of Transthyretin Amyloid Cardiomyopathy in a Single Patient: A Case Report on Diagnostic Challenge

International Medical Case Reports Journal
Lingling Yao,1,* Kexin Chen,1,* Fusheng Zhang,1 Jun Qin2 1Cardiac Care Unit, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People’s Republic of China; 2Department of Hematopathology, Renmin Hospital, Hubei University of ...
Yao L, Chen K, Zhang F, Qin J
doaj  

Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report

, 2017
Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR).
Takayuki Inomata, Yuichirou Iida, Toyoji Kaida, Shunsuke Ishii, Junya Ako, Eiji Kitamura, Emi Maekawa, Toshimi Koitabashi, Yuki Ikeda, Takashi Naruke, Teppei Fujita, Yoshiki Sekijima, Takeru Nabeta   +12 more
core   +1 more source

Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy.

Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin ...
Schwarting, Stéphanie Kristina;Bieber, Thomas;Davies, Daniel R;Aus dem Siepen, Fabian;Schwarting, Julian;Grabmaier, Ulrich;Massberg, Steffen;Maurer, Mathew S;Kääb, Stefan
core   +1 more source

Tafamidis in the Treatment of ATTR-related Cardiomyopathy

: Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers.
Lalario, Andrea, Rossi, Maddalena, Porcari, Aldostefano, Emdin, Michele, Sinagra, Gianfranco, Aimo, Alberto, Limongelli, Giuseppe, Capovilla, Teresa Maria, Merlo, Marco   +8 more
core   +1 more source

Early Detection of Polyneuropathy in Patients with Hereditary Transthyretin Amyloid Cardiomyopathy and Determining the Cost-Effective Treatment for Mixed Phenotype Patients [PDF]

Transthyretin amyloidosis is a rare disease caused by the deposits of misfolded proteins known as amyloid. This disease is caused by misfolded transthyretin (TTR) proteins, that are produced in the liver and are deposited in various organs and tissues ...
Arivalagan, Priya
core  

An alternative path in transthyretin amyloid cardiomyopathy

International audienceTransthyretin amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiomyopathy caused by myocardial transthyretin deposition that is increasingly recognised as a cause of heart failure[1,2].
Olesen, Anne Sophie O, Jhund, Pardeep, S, Girerd, Nicolas   +2 more
core   +1 more source

A Hemodynamic Echocardiographic Approach to Disease Severity and Prognosis in Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Serenelli M, Cantone A, Porcari A, Pozzan M, Merlo M, Sinagra G, Guidi Colombi G, Dal Passo B, Sanguettoli F, Arzenton M, Maio D, Vitali M, Casolari G, Bonini J, Cipriani A, De Michieli L, Mele D, Sinigiani G, Tomasoni D, Metra M, Pavasini R, Biscaglia S, Campo G.   +22 more
europepmc   +1 more source

Stage-dependent timing of relative and absolute treatment benefit in transthyretin amyloid cardiomyopathy. [PDF]

Open Heart
Nabeshima Y, Kaneko T, Yajima A, Node K, Takeuchi M.   +4 more
europepmc   +1 more source

Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Tang R, Patolia H, Shukla N, Rajendran J, El Helou MC, Agdamag A, Estep JD, Rubio AC, Hanna M, Martyn T.   +9 more
europepmc   +1 more source

Sex Differences in Presentation and Outcomes of Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Ciocca N, Fuentes Artiles R, Studer Bruengger A, Hugelshofer S, Stämpfli SF, Ehl NF, Pieczora L, Suter A, Pongan D, Ministrini S, Pfister O, Meyer P, Shiri I, Hunziker L, Hundertmark MJ, Gräni C.   +15 more
europepmc   +1 more source